ADHD

Mylan's generic version of Dexedrine is now available at US pharmacies in 3 dosage strengths.

The FDA has approved Quillichew ER extended-release chewable tablets for the treatment of ADHD in patients 6 years and older.

Study compare early use and long duration of stimulants versus non-stimulant therapy for ADHD.

Dyanavel XR extended-release oral suspension has received FDA approval for the treatment of ADHD in patients 6 years and older.

Chronic health conditions are on the rise among children, especially those living in poverty.

Children living in extreme poverty with conditions such as asthma or ADHD more likely to have other chronic conditions.

Because of the multifactorial nature and strong genetic component of ADHD, practitioners continue to speculate whether ADHD is due solely to improper brain functioning.

Attention-deficit/hyperactivity disorder has long been viewed as a pediatric condition, but it often lasts into adulthood.

Exposure to antidepressants during pregnancy does not impact a baby's risk for autism or attention-deficit/hyperactivity disorder after birth.

How many of these off-label uses have you seen before?

The FDA has approved Pfizer's chewable formulation of methylphenidate HCl (QuilliChew ER) for the treatment of ADHD in patients 6 years and older.

Mylan has launched a generic version of Teva Pharmaceuticals' Adderall in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 20 mg, and 30 mg doses.

The FDA today approved Tris Pharma's extended-release amphetamine oral suspension (Dyanavel XR) for the treatment of ADHD in children aged 6 years and older.

Young male patients tend to receive antipsychotic prescriptions more often than their female counterparts.

The FDA has added a new warning to the drug label of the methylphenidate transdermal system indicated for ADHD to describe permanent loss of skin color, also known as chemical leukoderma.

An increasing number of adults receiving prescription stimulant medications challenge the notion that ADHD is a children's condition and create new obstacles for pharmacists.

Four separate drug manufacturers have launched generic versions of Shire's Intuniv ADHD treatment for children aged 6 to 17 years.

The FDA had accepted for review Tris Pharma's New Drug Application for its extended-release liquid amphetamine to treat ADHD in children.

Children with attention-deficit/hyperactivity disorder may be more at risk for binge eating than their peers.

Even though Shire is seeking an adult indication for its investigational ADHD treatment, the FDA is requesting pediatric data before deliberating the drug's approval.

Shire's ADHD treatment, lisdexamfetamine dimesylate (Vyvanse), is now available in a 10-mg titration dose.

Nearly one in 5 adults with epilepsy show symptoms of attentiondeficit/ hyperactivity disorder (ADHD), according to a recent study.

ADHD and conduct disorder may be associated with increased alcohol and tobacco use in in young adolescents, a study indicates.

A study examining the frequently used pyrethroid pesticide deltamethrin suggests that the substance may affect the development of the brain's dopamine system, potentially increasing the risk of ADHD in children.

While evidence suggests that children with ADHD fare better when treated with both stimulant medication and behavior therapy, a study has found that many of the children who are prescribed ADHD medication do not receive psychotherapy.

The new test aids health care professionals and patients in determining whether a specific medication will address ADHD symptoms effectively.

About 17% of college students misuse stimulant medications prescribed for attention deficit hyperactivity disorder (ADHD), according to a new study published in the Clinical Child and Family Psychology Review.

Children born to parents with bipolar disorder have a strong likelihood of experiencing episodes of manic symptoms themselves.

Because there are similarities in the symptoms of bipolar disorder and attention-deficit/hyperactivity disorder, differentiating between the 2 psychiatric conditions can be challenging for clinicians.